• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Bone Health and Osteoporosis Foundation
  • Product
    • How it Works
    • The Benefits
    • Warranty and Rental Program
    • Patents & Intellectual Property
    • Order Now
  • Research
  • Testimonials
  • About
    • Mission, History and Values
    • Medical / Scientific Advisors
    • Executive Team
  • Home
  • Blog
  • FAQ
  • Contact
    • Try a Juvent for FREE
  • Shop Now
  • 1.877.758.8368

W. Andrew Hodge, M.D. Named to Juvent Medical Advisory Board

November 1, 2011 Leave a Comment

World Renowned Surgeon and Scientist, W. Andrew Hodge, M.D. is named Chairman of Juvent’s Medical Advisory Board

PALM BEACH GARDENS, F.L., Nov. 1, 2011 (LOCAL NEWSWIRE) — Juvent – Regenerative Technologies Corporation (RTC), a medical device using patented Dynamic Motion Therapy® (“DMT”) technology for improved muskuloskeltal strength, posture, stability, and enhancement of the circulatory system, announced today the appointment of W. Andrew Hodge, M.D., as the Chairman of the Medical Advisory Board.

Dr. Hodge has an extensive background specializing in arthritis surgery and musculoskeletal research and currently serves as an Adjunct Professor, in the Department of Mechanical Engineering at the University of Maine, Chief of Orthopaedic Surgery at Eastern Maine Medical Center and Adjunct Professor at Scripps Florida.

Dr. Hodge is a world renowned Orthopaedic Surgeon specializing in arthritis surgery and musculoskeletal research. He has been recognized for his accomplishments on CNN News, the Discovery Channel, and Science Magazine. In Boston, he completed special fellowship training at both Harvard University and Massachusetts Institute of Technology. During ten years of performing surgery, research, and teaching in the Harvard/MIT system he designed and directed the BioMotion Laboratory. Dr. Hodge founded the BioMotion Foundation in 1987 as a non-profit organization to support orthopaedic research and education world-wide.

In 1992 the BioMotion Foundation, now known as The Institute for Mobility and Longevity, was recruited to Palm Beach, Florida by Good Samaritan Medical Center. This clinical and research operation combined world class orthopaedic surgeons with the latest advances in bioengineering and computer technology. Dr. Hodge has past affiliations at MIT and the University of Florida and recently he became the first practicing physician in Florida to be appointed to The Scripps Research Institute at Scripps-Florida. Dr. Hodge has several patents on medical devices including the 3D Knee®, a revolutionary concept in knee replacement which provides high flexion capacity to cultures with these functional demands. Dr. Hodge currently travels extensively in the Europe, the Middle East and the Far East training surgeons on these new technologies and allowing the people in these countries to eliminate arthritic pain while still enjoying their lifestyles. In 2009 he was awarded the Ellis Island Medal of Honor for his world-wide humanitarian efforts in medicine. This award has been given to six U.S. presidents, numerous Nobel Prize winners, and others. In 2012, he accepted a position to head the Musculoskeletal Section of Eastern Maine Medical Center, a large, regional healthcare system and part of the Pioneer Accountable Care Organization of New England.

As the Chairman of the Medical Advisory Board of Regenerative Technologies Corporation, Dr. Hodge is the Company’s primary contact to the medical community, coordinating and directing all continuing research on its DMT technology for the prevention and treatment of osteoporosis.

Categories: Uncategorized

Reader Interactions

Leave a Comment Cancel

Footer

  • Home
  • User Testimonials
  • Medical Research
  • Contact
  • FAQs
  • Order Now
  • About
  • Benefits
  • Press
  • Blog
  • Privacy Policy

 


 

In the US it is considered investigational for the treatment of osteoporosis or improvement/maintenance of bone mineral density and our claims have not been reviewed or cleared by the FDA to treat any disease or condition. (2) Calculated over the 20+ year expected life of a Juvent. The JUVENT® Micro-Impact Platform® is Registered as a Class I medical device for exercise and rehabilitation. JUVENT products are covered by the following issued patents, pending patents and their foreign equivalents: 6,843,776 6,884,2277,094211 7,207,954 7,207,955 7,985,191 8,114,036 11/369,611 11/486,538. Juvent, Dynamic Motion Therapy, Micro-Impact Platform, and the symbol are Registered trademarks of Regenerative Technologies Corporation.

Juvent Clinical Studies Request

We protect and keep any given information confidentially.
  • This field is for validation purposes and should be left unchanged.

Juvent Health E-mail Signup

Get news, product updates and special offers in your inbox each month for free!

  • This field is for validation purposes and should be left unchanged.